Pfizer Inc. (NYSE:PFE) Shares Sold by Western Wealth Management LLC

Western Wealth Management LLC lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 12.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,658 shares of the biopharmaceutical company’s stock after selling 7,074 shares during the period. Western Wealth Management LLC’s holdings in Pfizer were worth $1,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. RB Capital Management LLC increased its holdings in Pfizer by 6.7% in the 1st quarter. RB Capital Management LLC now owns 5,446 shares of the biopharmaceutical company’s stock valued at $282,000 after purchasing an additional 341 shares during the last quarter. Ironwood Wealth Management LLC. increased its holdings in Pfizer by 1.1% in the 1st quarter. Ironwood Wealth Management LLC. now owns 36,081 shares of the biopharmaceutical company’s stock valued at $1,868,000 after purchasing an additional 400 shares during the last quarter. United Bank increased its holdings in Pfizer by 0.6% in the 1st quarter. United Bank now owns 46,671 shares of the biopharmaceutical company’s stock valued at $2,416,000 after purchasing an additional 290 shares during the last quarter. Ergoteles LLC boosted its position in Pfizer by 136.3% in the 1st quarter. Ergoteles LLC now owns 36,766 shares of the biopharmaceutical company’s stock valued at $1,903,000 after buying an additional 21,209 shares during the period. Finally, Mackenzie Financial Corp boosted its position in Pfizer by 6.4% in the 1st quarter. Mackenzie Financial Corp now owns 1,337,418 shares of the biopharmaceutical company’s stock valued at $69,238,000 after buying an additional 79,887 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $25.99 on Friday. Pfizer Inc. has a 1-year low of $25.23 and a 1-year high of $40.37. The stock has a market cap of $147.17 billion, a PE ratio of 72.19, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The firm has a fifty day moving average price of $27.11 and a 200 day moving average price of $28.68.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to analysts’ expectations of $14.37 billion. During the same period in the previous year, the company earned $1.14 earnings per share. Pfizer’s quarterly revenue was down 41.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current year.

Analysts Set New Price Targets

Several brokerages have commented on PFE. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Guggenheim began coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price target for the company. TD Cowen cut shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a research report on Thursday, January 4th. Finally, Argus cut shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Twelve analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $36.88.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.